December 6, 2016: As the end of the year approaches, there will be many “Best Of…” lists. Brian Orelli, writing for The Motley Fool, takes a little different spin, pointing out a handful of biotech bosses who made the biggest blunders of the year.
December 6, 2016: Despite problems with its blood testing technology and repeated questions of its efficacy, Theranos leaders apparently truly believed the technology would lead to revenue of just under $2B this year.
December 6, 2016: There has been a lot of positive news coming out of the American Society of Hematology meeting in California, with a number of MA companies making waves with data from key trials.
December 6, 2016: Ahead of President-Elect Donald Trump being sworn in on January 20 with promises to reform the FDA, John Jenkins, longtime director of the FDA’s Office of New Drugs will retire.